164 related articles for article (PubMed ID: 6231746)
21. Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (Macaca facicularis) brain.
Paterson IA; Davis BA; Durden DA; Juorio AV; Yu PH; Ivy G; Milgram W; Mendonca A; Wu P; Boulton AA
Neurochem Res; 1995 Dec; 20(12):1503-10. PubMed ID: 8789614
[TBL] [Abstract][Full Text] [Related]
22. Guinea pig striatum as a model of human dopamine deamination: the role of monoamine oxidase isozyme ratio, localization, and affinity for substrate in synaptic dopamine metabolism.
Azzaro AJ; King J; Kotzuk J; Schoepp DD; Frost J; Schochet S
J Neurochem; 1985 Sep; 45(3):949-56. PubMed ID: 3928811
[TBL] [Abstract][Full Text] [Related]
23. Identification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leaves.
Sloley BD; Urichuk LJ; Morley P; Durkin J; Shan JJ; Pang PK; Coutts RT
J Pharm Pharmacol; 2000 Apr; 52(4):451-9. PubMed ID: 10813558
[TBL] [Abstract][Full Text] [Related]
24. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
25. Regional brain variations of tryptophan, monoamines, monoamine oxidase activity, plasma free and total tryptophan during the estrous cycle of the rat.
Kueng W; Wirz-Justice A; Menzi R; Chappuis-Arndt E
Neuroendocrinology; 1976; 21(4):289-96. PubMed ID: 1035790
[TBL] [Abstract][Full Text] [Related]
26. (-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
Yáñez M; Fraiz N; Cano E; Orallo F
Eur J Pharmacol; 2006 Aug; 542(1-3):54-60. PubMed ID: 16828740
[TBL] [Abstract][Full Text] [Related]
27. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
28. Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant.
Seif-El-Nasr M; Atia AS; Abdelsalam RM
Arzneimittelforschung; 2008; 58(4):160-7. PubMed ID: 18540477
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours.
Finberg JP; Youdim MB
Neuropharmacology; 2002 Dec; 43(7):1110-8. PubMed ID: 12504917
[TBL] [Abstract][Full Text] [Related]
30. Ontogenesis of enzyme systems deaminating different monoamines.
Blatchford D; Holzbauer M
Br J Pharmacol; 1976 Jun; 57(2):279-93. PubMed ID: 938797
[TBL] [Abstract][Full Text] [Related]
31. Distribution of the two forms of monoamine oxidase within monoaminergic neurons of the guinea pig brain.
Ross SB
J Neurochem; 1987 Feb; 48(2):609-14. PubMed ID: 3098921
[TBL] [Abstract][Full Text] [Related]
32. Effects of cyanide in vitro on the activity of monoamine oxidase in striatal tissue from rat and pig.
Cassel GE; Persson SA; Stenström A
Biochem Pharmacol; 1994 Feb; 47(3):499-504. PubMed ID: 8117318
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase.
Zhou S; Chen G; Huang G
Bioorg Med Chem; 2018 Sep; 26(17):4863-4870. PubMed ID: 30143367
[TBL] [Abstract][Full Text] [Related]
34. Evidence for an extraneuronal location of monoamine oxidase in renal tissues.
Caramona MM; Soares-da-Silva P
Naunyn Schmiedebergs Arch Pharmacol; 1990 May; 341(5):411-3. PubMed ID: 2366877
[TBL] [Abstract][Full Text] [Related]
35. Immunity of fetal mice to prenatal administration of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Melamed E; Rosenthal J; Youdim MB
J Neurochem; 1990 Oct; 55(4):1427-31. PubMed ID: 2398363
[TBL] [Abstract][Full Text] [Related]
36. MAO activity in rat brain stem and cerebral cortex following acute and chronic treatment with L-dopa and ethanol + L-dopa.
Renis M; Giovine A; Bertolino A
Pharmacology; 1977; 15(5):392-9. PubMed ID: 918143
[TBL] [Abstract][Full Text] [Related]
37. Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues.
Celada P; Artigas F
J Neurochem; 1993 Dec; 61(6):2191-8. PubMed ID: 7504085
[TBL] [Abstract][Full Text] [Related]
38. Age-related changes on monoamine turnover in hippocampus of rats.
Venero JL; de la Roza C; Machado A; Cano J
Brain Res; 1993 Dec; 631(1):89-96. PubMed ID: 7507792
[TBL] [Abstract][Full Text] [Related]
39. Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids.
Thiblin I; Finn A; Ross SB; Stenfors C
Br J Pharmacol; 1999 Mar; 126(6):1301-6. PubMed ID: 10217522
[TBL] [Abstract][Full Text] [Related]
40. Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor.
Sagi Y; Weinstock M; Youdim MB
J Neurochem; 2003 Jul; 86(2):290-7. PubMed ID: 12871570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
